AEON Biopharma, Inc. AEON
AEON Biopharma, Inc. (NYSE: AEON) is a CNS/neurology/psychiatry drug developer. Its lead program, ABP-450, is in Pre-clinical for Botulinum toxin (351(k) biosimilar to Botox; neurology/aesthetic indications). Its next catalyst on record is ABP-450: Complete majority of analytical comparability program (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ABP-450 — Complete majority of analytical comparability program (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ABP-450 | Botox biosimilar (351(k)) | protein/peptide | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.